Key Highlights
● OrbiMed Advisors and two affiliated funds disclosed a new 11.0% stake of 6,885,170 shares in Electra Therapeutics on September 25, 2026.
● The position was built through preferred-stock conversions between 2022 and 2026 plus 1.33 million shares purchased in the company's IPO.
● OrbiMed's Carl L. Gordon sits on Electra's board and must route any director compensation he receives back to OrbiMed Advisors.
● The funds' shares are subject to a post-IPO lock-up that the filing says expires in March 2027.
OrbiMed Advisors and two affiliated Investment funds disclosed a new 11.0% stake in Electra Therapeutics, Inc. (NASDAQ:ETRA) in a Schedule 13D filed September 25, 2026, describing the position as held "for the purpose of making an investment" rather than to seek control. The filing reports OrbiMed Advisors as beneficially owning 6,885,170 shares of the biotechnology company, calculated against 62,766,955 shares outstanding as of September 18, 2026. The filing is the first Schedule 13D disclosing OrbiMed's position in Electra since the company's initial public offering.
Where the Shares Came From
According to the filing, OrbiMed's stake was built over several years and through Electra's initial public offering. Item 3 of the filing traces the acquisitions to conversions of preferred stock held between February 2022 and June 2026, plus common stock purchased directly in the IPO: 333,333 shares by OrbiMed Private Investments VII and 1,000,000 shares by OrbiMed Genesis Master Fund, both at $15.00 per share. The filing states the purchases were funded through the "working capital" of the two OrbiMed funds.
Three affiliated entities are named as reporting persons: OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC (the general partner of OPI VII) and OrbiMed Genesis GP LLC (general partner of the Genesis fund), with OrbiMed Capital GP VII reporting 5,126,891 shares (8.2%) and OrbiMed Genesis GP 1,758,279 shares (2.8%) of the aggregate stake. Key individuals named in the filing as members of OrbiMed's management committee include Carl L. Gordon, W. Carter Neild and Geoffrey C. Hsu, who share voting and dispositive authority over the funds' holdings.
Board Seat and Investor Rights
The filing discloses that OrbiMed's Carl L. Gordon sits on Electra's board of directors, and that under an agreement between Gordon and OrbiMed Advisors, he must transfer any director compensation or Equity awards he receives to OrbiMed Advisors, which in turn routes the economic benefit to OPI VII. The funds also hold registration rights, both Form S-1 and S-3 shelf registration rights, plus piggyback rights, and are subject to a post-IPO lock-up restriction on selling shares that the filing says expires in March 2027.
Item 4 of the filing states that beyond the general investment purpose, OrbiMed "has not formulated any plans or proposals" involving a sale of Electra's assets, an extraordinary corporate transaction, or changes to the board beyond Gordon's existing seat. The filing states OrbiMed intends to review its investment periodically, taking into account Electra's Business and financial condition as well as other investment opportunities, and may buy additional shares or sell some or all of its position depending on those ongoing evaluations.
Electra Therapeutics and OrbiMed
Electra Therapeutics is a clinical-stage biological products company, according to SEC classification codes referenced in the filing, and OrbiMed Advisors is a healthcare-focused registered investment adviser that manages the OrbiMed Private Investments and Genesis fund vehicles disclosed in this filing. A 13D, rather than the shorter-form 13G, is generally required when a filer's holdings include elements like board representation that go beyond a purely passive stake, consistent with Gordon's board seat here, even though the filing frames the overall purpose as investment-oriented.
OrbiMed is one of the larger healthcare-focused investment firms active in biotech financing, and its funds have historically taken board seats at early-stage life-sciences companies they back, consistent with Gordon's role at Electra.
Key Dates for OrbiMed's Electra Position
The lock-up restriction on OrbiMed's shares is disclosed as expiring in March 2027, a date investors may watch for potential share sales. Any future increase or decrease in OrbiMed's stake, or a change in stated purpose, would require a Schedule 13D amendment. The filing does not disclose any specific timeline for exercising the registration rights described in Item 6, including whether OrbiMed intends to file a resale registration statement covering its shares before the lock-up expires.






Please wait processing your request...